Trinity Capital Inc. reports developments as an alternative asset manager and specialty lender focused on private credit for growth-oriented companies. Its recurring news includes quarterly financial results, net investment income, NAV movement, new commitments, funded investments, repayments, exits, and portfolio activity across Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences.
Company updates also cover secured loans, equipment financings, warrant and equity investments, sponsored investment funds, SBIC-related activity, and growth-capital facilities for portfolio companies in technology, life sciences, medical technology, energy infrastructure, and other innovation-driven markets.
Trinity Capital (NASDAQ: TRIN) has appointed Zach Taffet as Director of Capital Formation & Investor Relations to strengthen its institutional fundraising initiatives. Taffet, who previously served on BlackRock's Infrastructure Capital Formation Team, brings nearly a decade of experience in capital raising and investor relations.
During his tenure at BlackRock, Taffet was instrumental in securing $13 billion in institutional capital commitments across multiple funds and played a important role in launching the franchise's fifth vintage fund. In his new role at Trinity, he will help drive the strategic direction for the company's private fund strategies and manage institutional capital through its RIA platform.
Trinity Capital Inc. (NASDAQ: TRIN) has announced the appointment of John Orlando as Managing Director of Life Sciences, based in Boston, expanding its presence to the East Coast. Orlando, who brings over a decade of venture lending experience, joins from Flagship Pioneering where he led debt advisory functions. Prior to this, he provided debt and banking services at J.P. Morgan and Pacific Western Bank.
The appointment strengthens Trinity's Life Sciences division, with Orlando reporting to Rob Lake, Senior Managing Director of Life Sciences. The move signals Trinity's strategic expansion in the Northeast region, leveraging Orlando's industry relationships and expertise in venture lending.
Trinity Capital (TRIN) reported strong Q4 and full-year 2024 results, marking significant growth across key metrics. Q4 highlights include total investment income of $70.8 million (up 48.1% YoY), record net investment income of $34.6 million ($0.58 per share), and a 17.4% Return on Average Equity.
The company achieved total gross investments of $297.3 million in Q4, including $233.4 million in 9 new portfolio companies. Full-year 2024 performance showed total investment income of $237.7 million (30.7% YoY increase) and net investment income of $115.8 million ($2.20 per share). Platform assets under management grew 40.6% to $2.0 billion.
The investment portfolio's fair value reached $1.73 billion, comprising 76.5% first-lien loans. The company maintained strong liquidity with $496.6 million available and expanded its KeyBank Credit Facility to $600 million.
Trinity Capital (NASDAQ: TRIN) has committed $15 million in growth capital to Cagent Vascular, a medical device company specializing in serration technology for vessel dilation in endovascular interventions. This funding complements a $45 million equity financing round led by US Venture Partners in 2024.
Cagent Vascular's flagship product, Serranator®, enhances angioplasty procedures by providing more controlled lumen gain with minimal dissection while reducing vessel recoil. The technology has been utilized in over 20,000 procedures and will use the new funding to scale commercial infrastructure and accelerate clinical adoption.
Trinity Capital (Nasdaq: TRIN) has released preliminary financial estimates for Q4 and full-year 2024. The company expects Q4 2024 net investment income between $0.58 to $0.60 per share, with net asset value per share estimated between $13.32 to $13.37 as of December 31, 2024.
The alternative asset manager reports investment assets at fair value of approximately $1.7 billion. The company's non-accrual investments represented about 0.8% of the total debt investment portfolio at fair value and 2.6% at cost as of year-end 2024.
Trinity Capital (NASDAQ: TRIN) has announced a $25 million growth capital commitment to Wisetack, a pay-over-time platform specializing in home services financing. Wisetack's platform integrates with existing home service business software, enabling services like HVAC, plumbing, and pest control providers to offer flexible payment options to their customers.
The capital will be used to scale Wisetack's operations and fund growth initiatives. Ryan Thompson, Managing Director of Tech Lending at Trinity Capital, highlighted Wisetack's exceptional growth trajectory, customer experience, and strong market position as key factors in the investment decision. Wisetack's founder and CEO, Bobby Tzekin, emphasized that the partnership will help accelerate their growth and innovation in the home services market.
Trinity Capital Inc. (Nasdaq: TRIN) has received confirmation of its investment grade credit rating of 'BBB (low)' with a stable outlook from Morningstar DBRS. This confirmation was announced by Trinity, a leading alternative asset manager. Morningstar DBRS, which rates over 4,000 issuers and 60,000 securities globally, is recognized as the fourth-largest credit rating agency worldwide and maintains a leading position in Canada, the United States, and Europe across multiple asset classes.
Trinity Capital (NASDAQ: TRIN) has committed $30 million in growth capital to Elucent Medical, a medical technology company specializing in guided surgical technologies. Elucent's flagship product, the EnVisio® System, utilizes In-Body Spatial Intelligence™ to provide physicians with 3D surgical awareness through spatial field generation and SmartClip® markers.
The investment follows Elucent's $44 million Series C funding round earlier in 2024. The new capital will support scaling operations and advancing commercialization efforts. The EnVisio® System transforms standard instruments into smart tools, enabling precise soft-tissue surgical excision through continuous 3D positioning data.
Trinity Capital Inc. (TRIN) has announced its earnings release schedule and conference call details for 2025. The company will release quarterly earnings before market opens, followed by conference calls at 12:00 p.m. ET on the following dates: February 26 (Q4/FY 2024), May 7 (Q1 2025), August 6 (Q2 2025), and November 5 (Q3 2025).
For the Q4/FY 2024 call, investors can dial (800) 267-6316 or (203) 518-9783 internationally, using Conference ID: TRINQ424. A replay will be available until March 5, 2025, accessible at (800) 723-0389 or (402) 220-2647. A live webcast will be available on the company's investor relations website, with the replay accessible for 90 days.
Trinity Capital (NASDAQ: TRIN) has announced a significant milestone: its equipment finance vertical has exceeded $1 billion in fundings to high-growth companies since 2018. The achievement highlights the company's role in supporting business growth across various sectors, including manufacturing & automation, energy, space technology, climate tech, and artificial intelligence.
The company has established itself as a key player in capital expenditure financing, supporting notable companies like Hermeus Corp., DrinkPAK, Hadrian Automation, Rocket Lab USA, and Dandelion Energy. This financing solution enables companies to access capital without equity dilution, strengthening their capital structure.
The cited fundings include debt investments made through Trinity Capital's predecessor funds (launched in 2008) until January 16, 2020, when these funds merged with Trinity Capital as it began operating as a business development company.